Axsome moves toward NDA filing for narcolepsy drug after Phase 3 data

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically significant improvement in the frequency of cataplexy attacks in narcoleptic patients compared with placebo. The company now ...